Using CAIX-targeted PET imaging for kidney cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of CAIX-targeted PET imaging in diagnosing and staging kidney cancer. It involves analyzing images by experienced physicians and comparing the results with histopathological findings from biopsies or surgeries. The study aims to assess the imaging's role in prognosis prediction and treatment evaluation by measuring various diagnostic metrics. Statistical methods will be employed to compare the performance of this imaging technique against enhanced CT scans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntary participation with the patient or their legal representative able to sign the informed consent form.
2. Adult patients (age between 18 and 75 years), regardless of gender.
3. Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).
4. Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.
5. ECOG performance status score of 0-3.
6. Laboratory parameters must meet the following criteria:

   1. ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.
   2. Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L.
7. Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.

Exclusion Criteria:

1. Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).
2. Patients or their legal representatives who are unable or unwilling to sign the informed consent form.
3. Acute systemic diseases and electrolyte imbalances.
4. Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).
5. Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.

Where it's running

• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000
  Xiamen, China Recruiting

Study contacts

• Study coordinator: Haojun Chen
• Email: leochen0821@foxmail.com
• Phone: 86-592-2137077

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a new imaging method for clear cell renal cell carcinoma

  This study is testing a new imaging method using a special probe to see if it can better help doctors diagnose clear cell renal cell carcinoma in Chinese patients compared to the standard imaging method.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT06519760

• 68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors

  A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885436

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Anxiety and Depression in Patients with Hematologic Cancers

  This study tests whether anxiety and depression levels before and after treatment are linked to treatment outcomes in people newly diagnosed with lymphoma, multiple myeloma, or leukemia.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07883070

• VCC combination in relapsed or refractory AML

  A group of adults with relapsed or refractory AML will receive a three-drug combo (venetoclax, chidamide, and chiglitazar sodium) to see if it helps control the leukemia.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07783100

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.